Cargando…

Phase 1 Study of Ceritinib Combined With Trametinib in Patients With Advanced ALK- or ROS1-Positive NSCLC

INTRODUCTION: In patients with NSCLC harboring oncogenic ALK or ROS1 rearrangements, tyrosine kinase inhibitors have yielded high response rates and improvements in progression-free survival compared with cytotoxic chemotherapy; however, acquired resistance eventually develops. In preclinical models...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lara, Matthew S., Gubens, Matthew A., Bacaltos, Bianca, Daran, Lea, Lim, Steffany L., Li, Tianhong, Gandara, David R., Bivona, Trever G., Riess, Jonathan W., Blakely, Collin M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9761844/ https://www.ncbi.nlm.nih.gov/pubmed/36545322 http://dx.doi.org/10.1016/j.jtocrr.2022.100436

Ejemplares similares

Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy
por: Santarpia, Mariacarmela, et al.
Publicado: (2017)

Afatinib reverses ceritinib resistance (CR) in ALK/ROS1-positive non-small-cell lung cancer cell (NSCLC) via suppression of NRG1 pathway
por: Chen, Hui, et al.
Publicado: (2018)

Targeting AXL in NSCLC
por: Zaman, Aubhishek, et al.
Publicado: (2021)

Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced ALK-Rearranged NSCLC: An ASCEND-4 Subgroup Analysis
por: Tan, Daniel S.W., et al.
Publicado: (2020)

Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib
por: van Erp, Anke E. M., et al.
Publicado: (2017)

Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib
por: Guan, Jikui, et al.
Publicado: (2018)

Ceritinib for ALK-Rearrangement–Positive Non–Small Cell Lung Cancer
por: Nix, Nancy M., et al.
Publicado: (2015)

The ALK inhibitors, alectinib and ceritinib, induce ALK‐independent and STAT3‐dependent glioblastoma cell death
por: Kawauchi, Daisuke, et al.
Publicado: (2021)

Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement
por: Krawczyk, Paweł, et al.
Publicado: (2021)

Non-Canonical Thinking for Targeting ALK-Fusion Onco-Proteins in Lung Cancer
por: Wu, Wei, et al.
Publicado: (2017)

AXL receptor tyrosine kinase as a therapeutic target in NSCLC
por: Okimoto, Ross A, et al.
Publicado: (2015)

Profile of ceritinib in the treatment of ALK+ metastatic non-small-cell lung cancer
por: Burns, Mark W, et al.
Publicado: (2015)

Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset
por: Kiura, Katsuyuki, et al.
Publicado: (2018)

Intracranial and whole-body response of ceritinib in ALK inhibitor-naïve and previously ALK inhibitor-treated patients with ALK-rearranged non-small-cell lung cancer (NSCLC): updated results from the phase 1, multicentre, open-label ASCEND-1 trial
por: Kim, Dong-Wan, et al.
Publicado: (2016)

Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution
por: Jonsson, Vanessa D., et al.
Publicado: (2017)

Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring KRAS Mutations
por: Arbour, Kathryn C., et al.
Publicado: (2021)

Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients
por: Lin, Luping, et al.
Publicado: (2012)

STRN-ALK Rearranged Malignant Peritoneal Mesothelioma With Dramatic Response Following Ceritinib Treatment
por: Rüschoff, Jan H., et al.
Publicado: (2019)

ALK Rearrangement Adenocarcinoma with Histological Transformation to Squamous Cell Carcinoma Resistant to Alectinib and Ceritinib
por: Kaiho, Taisuke, et al.
Publicado: (2020)

Pulmonary granulomatous inflammation after ceritinib treatment in advanced ALK-rearranged pulmonary adenocarcinoma
por: Liao, Juanyan, et al.
Publicado: (2022)

Successful rechallenge with ceritinib after leukocytoclastic vasculitis during ceritinib treatment for non-small cell lung cancer harboring the EML4-ALK fusion protein
por: Okimoto, Tamio, et al.
Publicado: (2018)

Rapamycin and trametinib: a rational combination for treatment of NSCLC
por: Sun, Chao-Yue, et al.
Publicado: (2021)

Activity of ceritinib in crizotinib-resistant ROS1-rearranged non-small-cell lung cancer patients
por: Zhang, Huixian, et al.
Publicado: (2023)

Organizing pneumonia in ALK+ lung adenocarcinoma treated with ceritinib: A case report and literature review
por: Wu, Yonghui, et al.
Publicado: (2021)

Neoadjuvant ceritinib treatment in ALK ‐rearranged locally advanced adenosquamous carcinoma: A case report
por: Mai, Shixiong, et al.
Publicado: (2022)

Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong
por: Loong, Herbert H., et al.
Publicado: (2020)

Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis
por: Hochmair, Maximilian J., et al.
Publicado: (2020)

Novel targeted therapies for resistant ALK-rearranged non-small-cell lung cancer: ceritinib and beyond
por: Kanaan, Zeyad, et al.
Publicado: (2015)

New treatment options for ALK+ advanced non-small-cell lung cancer: critical appraisal of ceritinib
por: Rothschild, Sacha I
Publicado: (2016)

Successful ceritinib treatment in a man with MPE and an ALK fusion gene mutation after multiple treatments
por: Wei, Hangping, et al.
Publicado: (2016)

Ceritinib Aggravates Glycemic Control in Insulin-treated Patients with Diabetes and Metastatic ALK-positive Lung Cancer
por: Sakuma, Ikki, et al.
Publicado: (2018)

ET-05 Alectinib and ceritinib, the second-generation ALK inhibitors, effectively induce glioblastoma cell death
por: Kawauchi, Daisuke, et al.
Publicado: (2020)

Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma
por: Subbiah, V., et al.
Publicado: (2021)

Correction to “Neoadjuvant ceritinib treatment in ALK ‐rearranged locally advanced adenosquamous carcinoma: A case report”
Publicado: (2023)

ALK and NSCLC: Targeted therapy with ALK inhibitors
por: Hallberg, Bengt, et al.
Publicado: (2011)

ALK Inhibitors in the Treatment of ALK Positive NSCLC
por: Khan, Muhammad, et al.
Publicado: (2019)

Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study
por: Ji, Jingran, et al.
Publicado: (2023)

Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced ALK- or ROS1-Rearranged NSCLC: A Brief Report
por: Thummalapalli, Rohit, et al.
Publicado: (2023)

Personalized treatment options for ALK-positive metastatic non-small-cell lung cancer: potential role for Ceritinib
por: El-Osta, Hazem, et al.
Publicado: (2015)

Real-life experience of ceritinib in crizotinib-pretreated ALK(+) advanced non-small cell lung cancer patients
por: Cadranel, Jacques, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_f7bkejq7u96uoa4s0t12gg4q9b